{"entity":{"id":"nct06928389","kind":"trial","name":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial of Ivonescimab, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, now recruiting.","summary":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06928389 by Akeso, with 536 participants planned, started 2025-07-08 and due to reach its primary completion in 2027-05. Interventions recorded: Ivonescimab, docetaxel, Placebo, docetaxel. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06928389","url":"https://clinicaltrials.gov/study/NCT06928389"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["ivonescimab","docetaxel"],"companies":["akeso"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06928389","phase":"3","setting":"A Randomized, Double-blind, Multicenter Phase 3 Clinical Trial of Ivonescimab Versus Placebo, Combined With Docetaxel in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) That Has Progressed on or After PD-(L)1 Inhibitor-based Therapy","sponsor":"Akeso","enrolled":536,"outcomes":[]},"route":"/trials/nct06928389/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"}]}}